Views

The IRA provides Medicare with the opportunity to negotiate drug prices. While there is preliminary direction about how maximum fair price will be calculated, speculation exists regarding how the negotiation process will work, evolve over time, and impact other areas of drug innovation and physician reimbursement. There is also the potential for other less obvious unintended market consequences that may change patient access to care, physician reimbursement, and pricing in other payer/purchaser segments beyond Medicare. Learn more in our recent article.

In the first in a three-part series, our Value Strategy and Services team in the United States provide an introduction to Pre-Approval Information Exchange and communicating Health Care Economic Information to payer audiences, including exploring current US Food and Drug Administration (FDA) guidance on payer communications.

Our experts share their views on the new AUS-CAN-UK Collaboration Arrangement.